Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-29

Inhibikase Therapeutics (IKT)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$30,586,007
Mark Iwicki total, FY2025
CEO pay percentile vs peers
CEO-to-median pay ratio
73.88%
Say-on-pay support, latest vote
Companies that benchmark against IKT
No companies currently name IKT as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Mark Iwicki$624,208$0$0$29,429,299$532,500$0$0$30,586,007
Chief Executive Officer and Director
Chris Cabell, M.D.429,167006,764,872281,250007,475,289
President and Head of Research and Development
David McIntyre347,216004,899,661272,813005,519,690
Chief Financial Officer
Milton Werner, Ph.D.728,9790040,44931,54302,092803,063
Former President and Chief Executive Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Mark Iwicki$30,586,007
Chris Cabell, M.D.7,475,289
David McIntyre5,519,690
Milton Werner, Ph.D.803,063

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Mark IwickiOption3,462,6372.35
Mark IwickiOption476,8572.97
Mark IwickiOption6,837,1802.35
Mark IwickiOption1,420,4802.35
David McIntyreOption1,775,5392
David McIntyreOption1,367,4282
CabellOption1,100,7052.97
CabellOption1,709,2952.97
05

Incentive-plan design — the Compensation Discussion & Analysis

CEO STI target (% of salary)
CEO LTI target (% of salary)
Independent consultant
Clawback policy
Anti-hedging
Anti-pledging
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-2661,237,30421,648,671222,74173.88%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-2673.88%a

a. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

09

Board fee structure and ownership guideline

Annual cash retainer$60,000
Annual equity retainer$150,000
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)24,000 / 18,000 / 12,000
Stock ownership guideline
10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Inhibikase Therapeutics2025Mark Iwicki$624,208$0$29,429,299$532,500$30,586,007

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Mark IwickiDEF 14A2026-04-300001193125-26-197177Section “Executive Compensation”. As printed: 30,586,007. Filing ↗machine: r2 · c16 · span 621587–621597
2Section 01, Chris Cabell, M.D.DEF 14A2026-04-300001193125-26-197177Section “Executive Compensation”. As printed: 7,475,289. Filing ↗machine: r4 · c16 · span 633751–633760
3Section 01, David McIntyreDEF 14A2026-04-300001193125-26-197177Section “Executive Compensation”. As printed: 5,519,690. Filing ↗machine: r6 · c16 · span 645920–645929
4Section 01, Milton Werner, Ph.D.DEF 14A2026-04-300001193125-26-197177Section “Executive Compensation”. As printed: 803,063. Filing ↗machine: r8 · c16 · span 658069–658076
5Section 06, 2026 voteForm 8-K2026-06-290001193125-26-286747Item 5.07 · say-on-pay result. As reported: 73.88% (votes for as printed: 61,237,304). Filing ↗
6Inhibikase Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-300001193125-26-197177CEO total compensation as printed in Inhibikase Therapeutics's own proxy. As printed: 30,586,007. Filing ↗machine: r2 · c16 · span 621587–621597